Global Deep Brain Stimulation Devices Market - 2022-2029

Global Deep Brain Stimulation Devices Market - 2022-2029

Market Overview

Deep Brain Stimulation Devices Market size was valued US$ 1.05 billion in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 8.4% during the forecast period (2022-2029).

Deep brain stimulation (DBS) devices are medical devices used in neurosurgical procedures to treat various neurological disorders. It works by sending the electrical impulses, through implanted electrodes, to the specific targets. It is implanted at one of the three brain sites, including the ventrointermedialis (VIM) nucleus of the thalamus, subthalamic nucleus (STN), and globus pallidus pars interna (GPi).

Market Dynamics

The rising R&D initiatives, rising demand for deep brain stimulation devices due to prevalence of neurological disorders, increased government funding and growing awareness towards these devices is driving the market's growth over the forecast period.

Increasing demand for deep brain stimulation products is expected to drive market growth.

The market is driven by the rising demand for deep brain stimulation products. The increase in the number of people undergoing deep brain stimulation (DBS) neurosurgical procedures and the increasing prevalence of neurological diseases, including epilepsy, Parkinson’s disease, and other disorders. According to an Andres M. Lozano et al. 2019 study, published in the Nature Reviews Neurology Journal, around 160,000 patients have undergone Deep Brain Stimulation to treat neurological and non-neurological conditions worldwide, and expected to increase every year. Epilepsy is the most common neurological disease. According to the World Health Organization (WHO), approximately 50 million people have epilepsy worldwide. According to the Parkinson’s Foundation, more than 10 million people have Parkinson's disease (PD) worldwide. It is more predominant among females in comparison to males.

The rise in the new product launch and approval shall stimulate market growth. For instance, in February 2019, Medtronic plc had launched Deep Brain Stimulation (DBS) for medically refractory epilepsy. It delivers the controlled electrical pulses to a brain target called the thalamus's anterior nucleus (ANT).

In January 2019, Boston Scientific Corporation had launched the Verse Primary Cell (PC) and Verse Gevia Deep Brain Stimulation (DBS) Systems featuring the Verse Cartesia Directional Lead. These systems feature the technology designed to allow physicians to control the range, shape, position, and direction of electrical stimulation to treat Parkinson’s disease (PD) symptoms through highly-personalized therapy.

The market is witnessing technological advancement in the development of novel Deep Brain Stimulation products. For instance, In January 2020, Abbott Laboratories had received expanded clearance from the Food and Drug Administration (US FDA) for the Infinity Deep Brain Stimulation system to include the targeting of an area of the brain called the internal globus pallidus (GPi) that plays a vital role in in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication. It is the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson's disease, and essential tremors. It operates through an iOS software platform with Bluetooth wireless technology. It also allows the clinicians to streamline the programming process with an iPad mini device using Abbott's new Infirmity Programming feature to become more efficient in their practice and achieve optimal outcomes with directional leads. Moreover, this system allows the patients to manage their Infinity DBS System iPod touch controller symptoms.

High cost associated with deep brain stimulation devices is expected to hamper the market growth.

Factors such as the high cost of instruments and risk associated with stimulation devices are expected to hinder the market's growth over the forecast period.

Industry Analysis

The global deep brain stimulation devices market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory and Reimbursement Analysis, Supply Chain Analysis, Pricing Analysis, Unmet Needs.

Segment Analysis/B>

Product type segment is expected to hold the largest market share in global deep brain stimulation devices market

The deep brain stimulation devices market is segmented on product type as a single-channel deep brain stimulator and dual-channel deep brain stimulator. The dual-channel deep brain stimulator segment accounts for the highest market share due to the high growth in deep brain stimulation devices' technological advancement with dual-channel deep brain stimulators. These devices are effective in simplifying the procedure for bilateral stimulation and enhancing the patient’s comfort level. A one-sided dual-channel deep brain stimulator provides the stimulation of electrical pulses through two DBS leads. There is an increase in the number of companies developing dual-channel deep brain stimulator with technological advancement. For instance, Medtronic’s Activa RC is a dual-channel, rechargeable neurostimulator for patients with high energy needs and has 15-year longevity. It delivers bilateral stimulation with a single device. It comprises the non-rechargeable battery and microelectronic circuitry to deliver a controlled electrical pulse to the brain's precisely targeted areas.

The single-channel deep brain stimulator segment is expected to have positive market growth over the forecasted period. The market is dominated by the availability of several single-channel deep brain stimulator devices. For instance, Medtronic’s ActivaTM SC is a single-channel device with a daily maintenance-free battery that provides predictable longevity. It is the smallest non-rechargeable device in the Activa portfolio or deep brain stimulation. It is implanted in the chest or abdomen, connected to an extension, and leads implanted in the brain. It can be used to treat Parkinson's disease, Dystonia, obsessive-compulsive disorder (OCD), and suppression of tremors.

Further, the market is also classified based on the application as Parkinson's Disease, Epilepsy, Essential Tremor, Dystonia, Obsessive-Compulsive Disorder, and Others. The Parkinson's Disease segment accounts for the highest market share due to the higher adoption of deep brain stimulation (DBS) devices to treat Parkinson's Disease. It is recommended to treat patients with Parkinson's disease for at least four years and benefit from medications but have motor complications. There is an increase in the number of novel deep brain stimulation device approvals for the treatment of Parkinson’s disease.

Geographical Analysis

North America region holds the largest market share in the global deep brain stimulation devices market

By region, the deep brain stimulation devices market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the deep brain stimulation devices market due to the increasing prevalence of Parkinson’s Disease and Epilepsy. According to the Parkinson’s Foundation, approximately 930,000 people are expected to be suffering from Parkinson’s Disease by 2020. It is further expected that the prevalence of cases would increase and reach up to 1.2 million by 2030. According to the Centres for Disease Control and Prevention (CDC), around 3 million adults and 470,000 children and teens below 18 years have Epilepsy. The United States is expected to have the highest market share. There is high technological advancement, including deep brain stimulation devices with enhanced microelectrode designs, multi-target stimulation, integrated implantable pulse generators, robot-assisted implantation, etc. High healthcare expenditure for healthcare facilities & infrastructures shall stimulate market growth. The North America region is expected to maintain its dominant position over the forecasted period.

The Asia Pacific region is expected to have positive market growth due to the increased number of people undergoing Deep Brain Stimulation neurosurgical procedures. The growing burden for treating neurological diseases has led companies to develop cost-effective deep brain stimulation devices, especially in China, Australia, and Japan. There is growing awareness regarding the diagnosis, treatment, and management of neurological disorders such as epilepsy, essential tremors, Parkinson’s disorder, etc. The increase in hospitals and neurology clinics will boost deep brain stimulation devices' demand over the forecasted period.

Competitive Landscape

The deep brain stimulation devices market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Boston Scientific Corporation., Aleva Neurotherapeutics SA, Medtronic Plc, Medtronic Plc, and Nevro Corporation

Abbott Laboratories, Aleva Neurotherapeutics SA, Boston Scientific Corporation, Medtronic Plc, NeuroPace Inc., Nevro Corporation, and Neuronetics Inc. are the leading market players with significant market share. In August 2019, Abbott Laboratories had expanded its deep brain stimulation (DBS) therapy by offering magnetic resonance (MR)-conditional labeling and innovative features.

In January 2020, Medtronic plc had received the European CE Mark approval for its deep brain stimulation device, i.e., Percept. It is the only Deep Brain Stimulation (DBS) system to be launched in the European Union (EU) with BrainSense technology that allows us to sense and record brain signals while delivering therapy to patients with neurologic disorders Parkinson’s disease. BrainSense technology enables physicians to track patient-specific brain signals and correlate these with patient-recorded events, such as symptoms or side effects associated with their disease or the medications to treat it.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to increase the demand for deep brain stimulation devices and their expansion across the globe. For instance, in October 2019, GTX medical had merged with US-based medical device developer NeuroRecovery Technologies (NRT) to create a neurostimulation company focusing on spinal cord injury (SCI). The merged entity would be known as GTX medical BV that would focus on developing neuromodulation therapies to improve people's functional recovery with SCI.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

Infinity DBS System: Infinity DBS is the first directional DBS system that has been approved for all key targets that are used for treatments like movement disorders, Parkinson's disease and Essential Tremor.

Key Developments: In July 2022, Abbott announced the Breakthrough Device Designation received grant from U.S. FDA for investigating its deep brain stimulation in TRD.

The global deep brain stimulation devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.